The Effects of PXR Activation on Hepatic Fat Content

• Status: Completed
• Trial end date: 2017-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates the effects of pregnane X receptor (PXR) activation on hepatic fat content in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to volunteers. Hepatic fat content is measured with magnetic resonance imaging and blood samples are collected at the end of each study arm. The investigators' hypothesis is that rifampicin causes accumulation of fat to the liver.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Oulu
• Collaborator: Oulu University Hospital
• Treatments: Rifampin

Criteria

Inclusion Criteria:

• Healthy volunteers

• Body mass index (BMI) 18.5-25 kg/m2

Exclusion Criteria:

• Systolic blood pressure over 150 mmHg

• Any continuous medication (hormonal intrauterine device is permitted)

• Any significant medical condition

• Insensitivity to rifampicin

• Pregnancy and lactation

• Previous difficult venipuncture

• Alcohol and medicine abuse and drug use

• Participation to any other pharmaceutical trial within on month of screening

• Claustrophobia

• Metal and other implants which are contraindications to MRI